Market Overview

Research and Markets: Actemra (Rheumatoid Arthritis) Forecast and Market Analysis Report Gives Forecasts up to 2022

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/bcqwlh/actemra) has announced the addition of GlobalData's new report "Actemra (Rheumatoid Arthritis) Forecast and Market Analysis" to their offering.

GlobalData has released its new PharmaPoint Drug Evaluation report, Actemra (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer's Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly's anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ's SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once they enter the market.

Actemra (tocilizumab) is a first-in-class recombinant humanized mAb of the IgG1 subclass that binds to the IL-6 receptor, thus blocking its ability to increase white blood cell production which increases joint inflammation. Also, by controlling IL-6 levels, iron levels remain in check as increased IL-6 depletes stored iron levels. In May 2012, Genentech announced that the SUMMACTA study met primary endpoints showing comparable efficacy of SC Actemra 162mg weekly compared to 8mg/kg IV of Actemra. ACR 20 was achieved in both groups by Week 24. Also, data released in June 2012, showed Actemra to be significantly more effective than Humira in a head-to-head trial; results are below in the efficacy section. Currently, Actemra is the only IL-6 inhibitor approved for the treatment of moderate to severe active RA.

Scope

- Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on Actemra including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for Actemra for the top 10 countries from 2012 to 2022.

- Sales information covered for the US, Japan, UK, France, Germany, Spain, Italy, India, China and Australia

For more information visit http://www.researchandmarkets.com/research/bcqwlh/actemra

Source: GlobalData

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Immune Disorders

 

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free